MarketCap
Facebook
X
TelegramAnnual report 2026
added 04-02-2026
IRIDEX Corporation Net Debt 2011-2026 | IRIX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt IRIDEX Corporation
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.23 M | -293 K | -4.29 M | -12.2 M | -8.97 M | - | -12.7 M | -21.2 M | -21.7 M | -10 M | -13.3 M | - | -13.4 M | -11.9 M | -8.35 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -293 K | -21.7 M | -11 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B |  USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.0 | -0.58 % | $ 1.62 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 9.15 | -2.51 % | $ 259 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 36.35 | -1.05 % | $ 5.42 K | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 15.71 | -1.44 % | $ 369 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.4 | -1.73 % | $ 127 M |  France |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Align Technology
ALGN
|
-925 M | $ 168.12 | -2.18 % | $ 12.6 B | USA |
 |
AxoGen
AXGN
|
15.2 M | $ 31.05 | -4.87 % | $ 1.43 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 4.01 | -2.91 % | $ 849 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.61 | 3.37 % | $ 38 M | USA |
 |
TELA Bio
TELA
|
5.33 M | $ 0.69 | 9.81 % | $ 32.4 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 9.65 | -0.52 % | $ 346 M | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.58 | -0.11 % | $ 122 M | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
9.26 B | $ 61.35 | -1.93 % | $ 90.8 B | USA |
 |
Alphatec Holdings
ATEC
|
347 M | $ 11.1 | 1.19 % | $ 1.67 B | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 34.34 | 0.81 % | $ 1.07 B | USA |
 |
Globus Medical
GMED
|
-511 M | $ 90.53 | 2.15 % | $ 12.2 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 80.81 | -0.42 % | $ 47.3 B | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.76 | -7.37 % | $ 1.07 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.31 | - | $ 717 M | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 54.8 | 1.25 % | $ 1.61 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 85.37 | -0.29 % | $ 2.97 B | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
-10.2 M | $ 5.84 | -0.85 % | $ 69.8 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
23.6 B | $ 86.48 | 0.22 % | $ 111 B | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
Myomo
MYO
|
-4.79 M | $ 0.67 | -4.29 % | $ 28 M | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |